Sfoglia per Autore
Phase II trial of sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC)
2007-01-01 Cupini, S.; Bursi, S.; Masi, G.; Loupakis, F.; Barbara, C.; Fornaro, L.; Allegrini, G.; DI MARSICO, R.; Andreuccetti, M.; Falcone, Alfredo
Phase III Trial of infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) compared with infusional Fluorouracil,Leucovorin, and Irinotecan (FOLFIRI) as first-line treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest(G.O.N.O.)
2007-01-01 Falcone, Alfredo; Ricci, S.; Brunetti, I.; Pfanner, E.; Allegrini, G.; Barbara, C.; Crin, L.; Benedetti, G.; Evangelista, W.; Fanchini, L.; Cortesi, E.; Picone, V.; Vitello, S.; Chiara, S.; Granetto, C.; Porcile, G.; Fioretto, L.; Orlandini, C.; Andreuccetti, M.; Masi, G.
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine ( C ), irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI): a pilot study by the Gruppo Oncologico Nord Ovest (G.O.N.O.)
2007-01-01 Bursi, S.; Masi, G.; Loupakis, F.; Antonuzzo, A.; Tognarini, L.; Sonaglio, C.; Chiara, S.; Pfanner, E.; Brunetti, I.; Petrini, Iacopo; Baldi, G. G.; Barletta, M. T.; Fornaro, L.; Allegrini, G.; Donati, S.; Andreuccetti, M.; Ricci, S.; Falcone, Alfredo
Pharmacogenetic profiling for anti-epidermal growth factor receptor (EGFR) therapy in (pts) with refractory advanced colorectal cancer (ACRC)
2007-01-01 Graziano, F.; Ruzzo, A.; Loupakis, F.; Floriani, I.; Canestrari, E.; Santini, D.; Catalano, V.; Torresi, U.; Bisonni, R.; Masi, G.; Schiavon, G.; Andreoni, F.; Maltese, P.; Giustini, L.; Falcone, Alfredo; Tonini, G.; Rulli, E.; Fontana, A.; Mari, D.; Magnani, M.
Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity.
2007-01-01 Loupakis, F.; Falcone, Alfredo; Masi, G.; Fioravanti, Anna; Kerbel, R. S.; Del Tacca, M.; Bocci, Guido
Loss of PTEN expression in colorectal cancer (CRC) metastases (mets) but not in primary tumors predicts lack of activity of cetuximab plus irinotecan treatment
2008-01-01 Irene, Stasi; Fotios, Loupakis; Luca, Pollina; Masi, Gianluca; Nicola, Funel; Mario, Scartozzi; Petrini, Iacopo; Daniele, Santini; Stefano, Cascinu; Falcone, Alfredo
Chemotherapy without monoclonal antibodies in the treatment of metastatic colorectal cancer: Role of Triplets
2008-01-01 Falcone, Alfredo; Loupakis, F.; Vasile, E.; Masi, G.
Optimal strategy to increase the respectability of liver/lung metastases
2008-01-01 Falcone, Alfredo; Loupakis, F.; Vasile, E.; Masi, G.
Pten expression and Kras mutations as predictors of benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS)
2008-01-01 Loupakis, F.; Stasi, I.; Pollina, L.; Ruzzo, A.; Masi, G.; Cremolini, Chiara; Funel, N.; Fornaro, L.; Baldi, G. G.; Salvatore, L.; Cupini, S.; Petrini, Iacopo; Scartozzi, M.; Floriani, I.; Santini, D.; Cascinu, S.; Ricci, S.; Tonini, G.; Magnani, M.; Falcone, Alfredo
Outcome of initially unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases (mts)
2008-01-01 Masi, G.; Loupakis, F.; Fornaio, L.; Baldi, G.; Cupini, S.; DI DONATO, S.; Ferraldeschi, R.; Sonaglio, C.; Granetto, C.; Falcone, Alfredo
Epidermal growth factor receptor (EGFR) gene promoter methylation in primari colorectal tumours and corresponding metastatic sites: a new perspective for an “old”therapeutic target
2008-01-01 Pagliacci, A.; Scartozzi, M.; Bearzi, I.; Mandolesi, A.; Galizia, E.; Pierantoni, C.; Loupakis, F.; Berardi, R.; Zaniboni, A.; Quadri, A.; Zorzi, F.; Biscotti, T.; Labianca, R.; Masi, G.; Falcone, Alfredo; Cascinu, S.
Metronomic chemotherapy (MC) with UFT, cyclophosphamide (CTX) and celecoxib in patients with advanced gastrointestinal cancers: A clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations
2008-01-01 Allegrini, G.; Bocci, Guido; Barletta, M.; Fioravanti, A.; DI DESIDERIO, T.; Loupakis, F.; Masi, G.; Baldi, G.; DI MARSICO, R.; DEL TACCA, M.; DI LEO, A.; Brandi, G.; Andreuccetti, M.; Kerbel, R.; Falcone, Alfredo
Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primari tumors as predictors of activity of cetuximab plus irinotecan treatment
2008-01-01 Loupakis, F.; Pollina, L.; Stasi, I.; Masi, G.; Funel, N.; Scartozzi, M.; Petrini, Iacopo; Santini, D.; Cascinu, S.; Falcone, Alfredo
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients.
2008-01-01 Allegrini, G.; Falcone, Alfredo; Fioravanti, Anna; Barletta, M. T.; Orlandi, Paola; Loupakis, F.; Cerri, E.; Masi, G.; DI PAOLO, Antonello; Kerbel, R. S.; Danesi, Romano; Del Tacca, M.; Bocci, Guido
Phase II capecitabine and gemcitabine fixed dose rate (FDR) in patients with advanced pancreatic cancer
2008-01-01 Santini, D.; Vincenzi, B.; Masi, G.; Catalano, V.; Virzi, V.; Vasile, E.; Fontana, A.; Intagliata, S.; Catalano, G.; Falcone, Alfredo; Tonini, G.
FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the G.O.N.O. group
2008-01-01 Falcone, Alfredo; Masi, G.; Loupakis, F.; Vasile, E.; Ciarlo, A.; Cavaciocchi, D.; Amoroso, D.; Puglisi, M.; Fea, E.; Brunetti, I.
First-line treatment of metastatic colorectal cancer (MCRC) with folfoxiri (irinotecan, oxaliplatin and infusional 5FU/LV) in combination with bevacizumab (BV): A phase II study by the G.O.N.O. Group
2008-01-01 Masi, G.; Loupakis, F.; Baldi, G.; Fornaro, L.; Stasi, I.; Vasile, E.; Ciarlo, A.; Cavaciocchi, D.; DI LEO, A.; Puglisi, M.; Ciprotti, M.; Amoroso, D.; Fea, E.; DI DONATO, S.; Falcone, Alfredo
Phase II study of irinotecan, oxaliplatin and infusional 5FU/LV (GONO-FOLFOXIRI) plus bevacizumab (BV) as first-line treatment in metastatic colorectal cancer (MCRC)
2008-01-01 Masi, G.; Loupakis, F.; Vasile, E.; Cupini, S.; Fornaro, L.; Baldi, G. G.; Stasi, I.; Salvatore, L.; Ciarlo, A.; Cavaciocchi, D.; Ciprotti, M.; Puglisi, M.; Rondini, M.; Puccinelli, P.; Granetto, C.; DI DONATO, S.; Antonuzzo, A.; DI MARSICO, R.; Andreuccetti, M.; Falcone, Alfredo
Pegfilgrastim to support chop-r chemotherapy administered every 14 days in patients (PTS) with aggressive B-cell non-Hodgkin’s lymphoma (NHL)
2008-01-01 Cupini, S.; Capochiani, E.; Bursi, S.; Landi, L.; Coltelli, L.; Giuntini, N.; LO DICO, M.; Mazzoni, E.; Baldi, G. G.; Barletta, M. T.; Fornaro, L.; Stasi, I.; Dincecco, A.; Salvatore, L.; Caponi, S.; Bona, E.; Battaglini, P.; Masi, G.; Falcone, Alfredo
K-RAS status in primary colorectal tumours correlate with K-RAS status in related metastatic sites: implications for treatment with anti-EGFR antibodies in clinical setting
2008-01-01 Santini, D.; Loupakis, F.; Vincenzi, B.; Perrone, G.; Graziano, F.; Floriani, I.; Maltese, P.; Stasi, I.; Canestrari, E.; Masi, G.; ONETTI MUDA, A.; Magnani, M.; Falcone, Alfredo; Ruzzo, A.; Tonini, G.
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
Phase II trial of sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC) | 1-gen-2007 | Cupini, S.; Bursi, S.; Masi, G.; Loupakis, F.; Barbara, C.; Fornaro, L.; Allegrini, G.; DI MARSICO, R.; Andreuccetti, M.; Falcone, Alfredo | |
Phase III Trial of infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) compared with infusional Fluorouracil,Leucovorin, and Irinotecan (FOLFIRI) as first-line treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest(G.O.N.O.) | 1-gen-2007 | Falcone, Alfredo; Ricci, S.; Brunetti, I.; Pfanner, E.; Allegrini, G.; Barbara, C.; Crin, L.; Benedetti, G.; Evangelista, W.; Fanchini, L.; Cortesi, E.; Picone, V.; Vitello, S.; Chiara, S.; Granetto, C.; Porcile, G.; Fioretto, L.; Orlandini, C.; Andreuccetti, M.; Masi, G. | |
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine ( C ), irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI): a pilot study by the Gruppo Oncologico Nord Ovest (G.O.N.O.) | 1-gen-2007 | Bursi, S.; Masi, G.; Loupakis, F.; Antonuzzo, A.; Tognarini, L.; Sonaglio, C.; Chiara, S.; Pfanner, E.; Brunetti, I.; Petrini, Iacopo; Baldi, G. G.; Barletta, M. T.; Fornaro, L.; Allegrini, G.; Donati, S.; Andreuccetti, M.; Ricci, S.; Falcone, Alfredo | |
Pharmacogenetic profiling for anti-epidermal growth factor receptor (EGFR) therapy in (pts) with refractory advanced colorectal cancer (ACRC) | 1-gen-2007 | Graziano, F.; Ruzzo, A.; Loupakis, F.; Floriani, I.; Canestrari, E.; Santini, D.; Catalano, V.; Torresi, U.; Bisonni, R.; Masi, G.; Schiavon, G.; Andreoni, F.; Maltese, P.; Giustini, L.; Falcone, Alfredo; Tonini, G.; Rulli, E.; Fontana, A.; Mari, D.; Magnani, M. | |
Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. | 1-gen-2007 | Loupakis, F.; Falcone, Alfredo; Masi, G.; Fioravanti, Anna; Kerbel, R. S.; Del Tacca, M.; Bocci, Guido | |
Loss of PTEN expression in colorectal cancer (CRC) metastases (mets) but not in primary tumors predicts lack of activity of cetuximab plus irinotecan treatment | 1-gen-2008 | Irene, Stasi; Fotios, Loupakis; Luca, Pollina; Masi, Gianluca; Nicola, Funel; Mario, Scartozzi; Petrini, Iacopo; Daniele, Santini; Stefano, Cascinu; Falcone, Alfredo | |
Chemotherapy without monoclonal antibodies in the treatment of metastatic colorectal cancer: Role of Triplets | 1-gen-2008 | Falcone, Alfredo; Loupakis, F.; Vasile, E.; Masi, G. | |
Optimal strategy to increase the respectability of liver/lung metastases | 1-gen-2008 | Falcone, Alfredo; Loupakis, F.; Vasile, E.; Masi, G. | |
Pten expression and Kras mutations as predictors of benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) | 1-gen-2008 | Loupakis, F.; Stasi, I.; Pollina, L.; Ruzzo, A.; Masi, G.; Cremolini, Chiara; Funel, N.; Fornaro, L.; Baldi, G. G.; Salvatore, L.; Cupini, S.; Petrini, Iacopo; Scartozzi, M.; Floriani, I.; Santini, D.; Cascinu, S.; Ricci, S.; Tonini, G.; Magnani, M.; Falcone, Alfredo | |
Outcome of initially unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases (mts) | 1-gen-2008 | Masi, G.; Loupakis, F.; Fornaio, L.; Baldi, G.; Cupini, S.; DI DONATO, S.; Ferraldeschi, R.; Sonaglio, C.; Granetto, C.; Falcone, Alfredo | |
Epidermal growth factor receptor (EGFR) gene promoter methylation in primari colorectal tumours and corresponding metastatic sites: a new perspective for an “old”therapeutic target | 1-gen-2008 | Pagliacci, A.; Scartozzi, M.; Bearzi, I.; Mandolesi, A.; Galizia, E.; Pierantoni, C.; Loupakis, F.; Berardi, R.; Zaniboni, A.; Quadri, A.; Zorzi, F.; Biscotti, T.; Labianca, R.; Masi, G.; Falcone, Alfredo; Cascinu, S. | |
Metronomic chemotherapy (MC) with UFT, cyclophosphamide (CTX) and celecoxib in patients with advanced gastrointestinal cancers: A clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations | 1-gen-2008 | Allegrini, G.; Bocci, Guido; Barletta, M.; Fioravanti, A.; DI DESIDERIO, T.; Loupakis, F.; Masi, G.; Baldi, G.; DI MARSICO, R.; DEL TACCA, M.; DI LEO, A.; Brandi, G.; Andreuccetti, M.; Kerbel, R.; Falcone, Alfredo | |
Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primari tumors as predictors of activity of cetuximab plus irinotecan treatment | 1-gen-2008 | Loupakis, F.; Pollina, L.; Stasi, I.; Masi, G.; Funel, N.; Scartozzi, M.; Petrini, Iacopo; Santini, D.; Cascinu, S.; Falcone, Alfredo | |
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. | 1-gen-2008 | Allegrini, G.; Falcone, Alfredo; Fioravanti, Anna; Barletta, M. T.; Orlandi, Paola; Loupakis, F.; Cerri, E.; Masi, G.; DI PAOLO, Antonello; Kerbel, R. S.; Danesi, Romano; Del Tacca, M.; Bocci, Guido | |
Phase II capecitabine and gemcitabine fixed dose rate (FDR) in patients with advanced pancreatic cancer | 1-gen-2008 | Santini, D.; Vincenzi, B.; Masi, G.; Catalano, V.; Virzi, V.; Vasile, E.; Fontana, A.; Intagliata, S.; Catalano, G.; Falcone, Alfredo; Tonini, G. | |
FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the G.O.N.O. group | 1-gen-2008 | Falcone, Alfredo; Masi, G.; Loupakis, F.; Vasile, E.; Ciarlo, A.; Cavaciocchi, D.; Amoroso, D.; Puglisi, M.; Fea, E.; Brunetti, I. | |
First-line treatment of metastatic colorectal cancer (MCRC) with folfoxiri (irinotecan, oxaliplatin and infusional 5FU/LV) in combination with bevacizumab (BV): A phase II study by the G.O.N.O. Group | 1-gen-2008 | Masi, G.; Loupakis, F.; Baldi, G.; Fornaro, L.; Stasi, I.; Vasile, E.; Ciarlo, A.; Cavaciocchi, D.; DI LEO, A.; Puglisi, M.; Ciprotti, M.; Amoroso, D.; Fea, E.; DI DONATO, S.; Falcone, Alfredo | |
Phase II study of irinotecan, oxaliplatin and infusional 5FU/LV (GONO-FOLFOXIRI) plus bevacizumab (BV) as first-line treatment in metastatic colorectal cancer (MCRC) | 1-gen-2008 | Masi, G.; Loupakis, F.; Vasile, E.; Cupini, S.; Fornaro, L.; Baldi, G. G.; Stasi, I.; Salvatore, L.; Ciarlo, A.; Cavaciocchi, D.; Ciprotti, M.; Puglisi, M.; Rondini, M.; Puccinelli, P.; Granetto, C.; DI DONATO, S.; Antonuzzo, A.; DI MARSICO, R.; Andreuccetti, M.; Falcone, Alfredo | |
Pegfilgrastim to support chop-r chemotherapy administered every 14 days in patients (PTS) with aggressive B-cell non-Hodgkin’s lymphoma (NHL) | 1-gen-2008 | Cupini, S.; Capochiani, E.; Bursi, S.; Landi, L.; Coltelli, L.; Giuntini, N.; LO DICO, M.; Mazzoni, E.; Baldi, G. G.; Barletta, M. T.; Fornaro, L.; Stasi, I.; Dincecco, A.; Salvatore, L.; Caponi, S.; Bona, E.; Battaglini, P.; Masi, G.; Falcone, Alfredo | |
K-RAS status in primary colorectal tumours correlate with K-RAS status in related metastatic sites: implications for treatment with anti-EGFR antibodies in clinical setting | 1-gen-2008 | Santini, D.; Loupakis, F.; Vincenzi, B.; Perrone, G.; Graziano, F.; Floriani, I.; Maltese, P.; Stasi, I.; Canestrari, E.; Masi, G.; ONETTI MUDA, A.; Magnani, M.; Falcone, Alfredo; Ruzzo, A.; Tonini, G. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile